Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NTRA

Natera Inc

322.10

Aug 07 • 3:59 PM ET +56.72 (21.37%)

320.05

Aftermarket • 7:58 PM ET -2.05 (-0.64%)

Healthcare Diagnostics & Research USA Large NASD

Aug 07, 2:20 PMNatera beats Q2 estimates with non-GAAP EPS -$0.47 (+36% YoY), raises 2026 revenue guidance, BTIG and JPMorgan lift price targets to $320 and $360

Peers: IQV LH ICLR IDXX A DHR TMO WAT MTD BIO

| Held by: VTI VB VBK VXF IBB IWP IWR IWF JGRO XBI

Scroll to Statements

Index	-
Market Cap	46.13B
Enterprise Value	45.28B
Income	-192.35M
Sales	2.71B
Book/sh	12.68
Cash/sh	7.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6140
IPO	Jul 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	17.04
P/B	25.40
P/C	42.26
P/FCF	547.86
EV/EBITDA	-
EV/Sales	16.73
Quick Ratio	2.85
Current Ratio	3.00
Debt/Eq	0.13
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-1.37
EPS next Y	-0.12
EPS next Q	-0.23
EPS this Y	10.29%
EPS next Y	91.04%
EPS next 5Y	-
EPS past 3/5Y	35.09% 11.70%
Sales past 3/5Y	41.14% 42.61%
EPS Y/Y TTM	28.02%
Sales Y/Y TTM	37.82%
EPS Q/Q	36.85%
Sales Q/Q	37.71%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	4.84% 13.84%

Insider Own	4.40%
Insider Trans	-9.25%
Inst Own	92.57%
Inst Trans	1.47%
ROA	-8.71%
ROE	-12.54%
ROIC	-9.79%
Gross Margin	64.74%
Oper. Margin	-10.56%
Profit Margin	-7.11%
SMA20	19.43%
SMA50	27.53%
SMA200	44.38%
Trades

Shs Outstand	143.61M
Shs Float	136.92M
Short Float	3.63%
Short Ratio	3.30
Short Interest	4.96M
52W High	288.04 11.82%
52W Low	136.21 136.47%
Volatility	4.24% 4.22%
ATR (14)	14.65
RSI (14)	74.51
Beta	1.50
Rel Volume	2.25
Avg Volume	1.50M
Volume	3,386,988

Perf Week	20.29%
Perf Month	14.28%
Perf Quarter	46.53%
Perf Half Y	63.44%
Perf YTD	40.60%
Perf Year	128.31%
Perf 3Y	531.32%
Perf 5Y	174.60%
Perf 10Y	2535.84%
Recom	1.42
Target Price	317.33
Prev Close	265.38
Price	322.10
Change %	21.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Resumed	Bernstein	Outperform	$310
Jun-12-26	Resumed	RBC Capital Mkts	Outperform	$275
Jun-02-26	Resumed	Wolfe Research	Outperform	$260
Apr-14-26	Initiated	William Blair	Outperform
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76

Show Previous Ratings

Aug-07-26 01:55PM	These Two Biotech Stocks Hit Fresh 52-Week Highs Today NTRA Clocks Best Day In Nearly 20 Months (Stocktwits) +21.37%
10:42AM	SpaceX's influence ripples across markets: AlphaCheck (Yahoo Finance)
08:30AM	Natera, Inc. Q2 2026 Earnings Call Summary (Moby)
01:09AM	Natera Inc (NTRA) (Q2 2026) Earnings Call Highlights: Record Volumes and Raised Guidance Signal ... (GuruFocus.com)
Aug-06-26 05:30PM	Natera: Q2 Earnings Snapshot (Associated Press)
06:00AM	Loading…
Aug-05-26 06:00AM	Natera Submits Signatera to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (Business Wire)
Aug-03-26 04:06PM	Buffett-Inspired ETF Owns Berkshire, Apple, Amex and Generates 15% Yield (Barrons.com)
Jul-30-26 08:00AM	Natera to Report its Second Quarter Results on August 6, 2026 (Business Wire) +6.24%
Jul-22-26 06:00AM	Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study (Business Wire)
Jul-20-26 12:06PM	Cathie Wood Dumps $39 Million Worth of AMD Stock (GuruFocus.com)
Jul-16-26 06:35PM	Finalized MolDx LCD Includes Expanded Coverage for Nateras Prospera Portfolio (Business Wire)
08:13AM	Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It's Entering the U.S. (TSXV: SEGN) (FinanceWire)
Jul-13-26 12:52PM	Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group (GuruFocus.com)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com)
Jul-09-26 06:00AM	Natera Announces IVDR Certification for Signatera Across Multiple Cancers (Business Wire)
06:00AM	Loading…
Jul-06-26 06:00AM	Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer (Business Wire)
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 06:02PM	When Multi-Cancer Blood Screens Could Finally Take Off (Barrons.com)
05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-29-26 06:00AM	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer (Business Wire)
Jun-25-26 07:00AM	Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire)
Jun-24-26 05:00AM	Signatera Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire) +10.74%
Jun-23-26 06:00AM	NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update (Business Wire)
Jun-18-26 06:00AM	Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress (Business Wire)
Jun-05-26 10:40AM	Healthcare Stocks Can Benefit From AI, Too. But That Isn't the Reason to Buy Them. (Barrons.com)
09:36AM	Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Jun-04-26 08:00AM	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer (Business Wire)
Jun-03-26 08:00AM	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors (Business Wire)
May-29-26 06:00AM	Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma (Business Wire)
May-28-26 06:00AM	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer (Business Wire) +5.33%
06:00AM	Loading…
May-26-26 06:00AM	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology (Business Wire)
May-21-26 05:05PM	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology (Business Wire)
07:00AM	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World (Business Wire)
May-20-26 04:51PM	Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder (IPO-Edge.com)
07:00AM	EXPAND Trial of Nateras Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled (Business Wire)
May-15-26 05:18PM	Stanley Druckenmiller Exits State Street Financial Select Sector SPDR ETF, Impacting Portfolio ... (GuruFocus.com) -5.36%
12:45PM	Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) (Business Wire)
12:01AM	Nateras Stronghold in Cancer Recurrence Tests Prompts Woods Ark to Expand Stake (The Daily Upside)
May-14-26 05:30AM	The Cancer Test That Wall Street Is Betting On (The Wall Street Journal)
May-07-26 05:22PM	Natera: Q1 Earnings Snapshot (Associated Press) -11.64%
04:05PM	Natera Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
Apr-30-26 08:00AM	Natera to Report its First Quarter Results on May 7, 2026 (Business Wire) +5.86%
Apr-23-26 12:33PM	SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases (Exec Edge)
Apr-22-26 09:00AM	Prospera Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT (Business Wire)
Apr-13-26 08:00AM	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma (Business Wire)
Apr-09-26 06:00AM	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents (Business Wire)
Apr-07-26 06:00AM	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform (Business Wire)
Mar-31-26 06:00AM	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Business Wire) +7.04%
Mar-16-26 06:00AM	Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers (Business Wire) +5.23%
Mar-12-26 08:00AM	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis (Business Wire)
08:00AM	MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 (PR Newswire)
Mar-09-26 12:41AM	3 Healthcare Stocks to Target This Week (StockStory)
Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-17-26 04:01PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ... (GuruFocus.com)
09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Co-Founder & Executive ChairmanDr. Matthew Rabinowitz Ph.D.

CEO & DirectorMr. Steven Leonard Chapman

President & Chief Business OfficerMr. John Fesko

Chief Financial OfficerMr. Michael B. Brophy M.B.A.

President of Clinical DiagnosticsMr. Solomon Moshkevich M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 07 '26	Sale	320.90	2,000	641,800	2,000	Aug 07 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 07 '26	Sale	315.66	9,150	2,888,325	236,464	Aug 07 09:35 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Aug 07 '26	Proposed Sale	320.90	2,000	641,800		Aug 07 05:42 PM
Sheena Jonathan	Director	Aug 07 '26	Proposed Sale	330.62	18,000	5,951,100		Aug 07 10:41 AM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 04 '26	Sale	274.22	478	131,077	51,637	Aug 05 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 03 '26	Sale	267.99	317	84,953	52,115	Aug 05 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 03 '26	Sale	266.39	3,076	819,431	99,897	Aug 05 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 03 '26	Sale	267.99	295	79,057	183,774	Aug 05 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Aug 03 '26	Sale	265.58	3,410	905,627	129,019	Aug 05 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Aug 03 '26	Sale	267.99	334	89,508	170,073	Aug 05 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 03 '26	Sale	267.99	731	195,900	2,275,394	Aug 05 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 03 '26	Sale	267.99	109	29,211	245,614	Aug 05 09:35 PM
MICHAEL BROPHY	Officer	Aug 04 '26	Proposed Sale	270.36	478	129,232		Aug 04 04:36 PM
JONATHAN SHEENA	OFFICER	Aug 03 '26	Proposed Sale	267.76	108	28,918		Aug 03 04:22 PM
MATTHEW RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	722	193,323		Aug 03 04:22 PM
DANIEL RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	330	88,361		Aug 03 04:22 PM
SOLOMON MOSHKEVICH	OFFICER	Aug 03 '26	Proposed Sale	267.76	405	108,443		Aug 03 04:21 PM
JOHN FESKO	OFFICER	Aug 03 '26	Proposed Sale	267.76	292	78,186		Aug 03 04:21 PM
STEVEN CHAPMAN	OFFICER	Aug 03 '26	Proposed Sale	267.76	1,167	312,476		Aug 03 04:21 PM
MICHAEL BROPHY	OFFICER	Aug 03 '26	Proposed Sale	267.76	313	83,809		Aug 03 04:20 PM
STEVEN L CHAPMAN	Officer	Aug 03 '26	Proposed Sale	265.40	1,894	502,668		Aug 03 04:18 PM
SOLOMON MOSHKEVICH	Officer	Aug 03 '26	Proposed Sale	265.25	3,000	795,751		Aug 03 04:09 PM
Sheena Jonathan	CO-FOUNDER	Jul 27 '26	Sale	260.49	288	75,021	245,914	Jul 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jul 28 '26	Sale	254.07	191	48,527	245,723	Jul 29 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 27 '26	Sale	260.49	1,718	447,523	2,276,125	Jul 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 28 '26	Sale	254.07	1,003	254,833	170,407	Jul 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 27 '26	Sale	260.49	884	230,274	171,410	Jul 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 28 '26	Sale	254.07	1,204	305,901	132,429	Jul 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 27 '26	Sale	260.49	1,010	263,096	133,633	Jul 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 28 '26	Sale	254.07	931	236,540	184,069	Jul 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 27 '26	Sale	260.49	782	203,704	185,000	Jul 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 28 '26	Sale	254.07	3,580	909,572	102,973	Jul 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 27 '26	Sale	260.49	2,190	570,475	106,553	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 28 '26	Sale	253.96	2,419	614,336	54,295	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 29 '26	Sale	249.38	1,863	464,595	52,432	Jul 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 27 '26	Sale	260.49	782	203,704	56,714	Jul 29 09:35 PM
MICHAEL BROPHY	Officer	Jul 29 '26	Proposed Sale	252.22	1,863	469,886		Jul 29 04:21 PM
MICHAEL BROPHY	Officer	Jul 28 '26	Proposed Sale	258.03	1,178	303,959		Jul 28 04:40 PM
JONATHAN SHEENA	DIRECTOR	Jul 28 '26	Proposed Sale	258.03	188	48,510		Jul 28 04:08 PM
DANIEL RABINOWITZ	OFFICER	Jul 28 '26	Proposed Sale	258.03	988	254,934		Jul 28 04:08 PM
SOLOMON MOSHKEVICH	OFFICER	Jul 28 '26	Proposed Sale	258.03	1,185	305,766		Jul 28 04:08 PM
JOH N FESKO	OFFICER	Jul 28 '26	Proposed Sale	258.03	917	236,614		Jul 28 04:08 PM
STEVEN CHAPMAN	OFFICER	Jul 28 '26	Proposed Sale	258.03	3,525	909,556		Jul 28 04:07 PM
MICHAEL BROPHY	OFFICER	Jul 28 '26	Proposed Sale	258.03	1,222	315,313		Jul 28 04:07 PM
JONATHAN SHEENA	DIRECTOR	Jul 27 '26	Proposed Sale	261.99	285	74,667		Jul 27 03:36 PM
MATTHEW RABINOWITZ	DIRECTOR	Jul 27 '26	Proposed Sale	261.99	1,697	444,597		Jul 27 03:36 PM
DANIEL RABINOWITZ	OFFICER	Jul 27 '26	Proposed Sale	261.99	873	228,717		Jul 27 03:36 PM
SOLOMON MOSHKEVICH	OFFICER	Jul 27 '26	Proposed Sale	261.99	998	261,466		Jul 27 03:36 PM
JOHN FESKO	OFFICER	Jul 27 '26	Proposed Sale	261.99	772	202,256		Jul 27 03:36 PM
STEVEN CHAPMAN	OFFICER	Jul 27 '26	Proposed Sale	261.99	2,163	566,684		Jul 27 03:35 PM
MICHAEL BROPHY	OFFICER	Jul 27 '26	Proposed Sale	261.99	772	202,256		Jul 27 03:35 PM
Sheena Jonathan	CO-FOUNDER	Jul 15 '26	Sale	273.88	1,500	410,825	18,032	Jul 17 09:05 PM
Chapman Rowan E	Director	Jul 15 '26	Sale	274.82	135	37,101	4,663	Jul 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jul 13 '26	Sale	265.68	3,150	836,898	246,202	Jul 15 09:05 PM
ROWAN EMMA CHAPMAN	Director	Jul 15 '26	Proposed Sale	274.82	135	37,101		Jul 15 04:13 PM
Sheena Jonathan	Director	Jul 15 '26	Proposed Sale	275.22	1,500	412,830		Jul 15 10:10 AM
Sheena Jonathan	Director	Jul 13 '26	Proposed Sale	266.22	9,450	2,515,779		Jul 13 11:05 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 06 '26	Sale	280.00	1,000	280,000	4,000	Jul 08 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 01 '26	Sale	272.29	16,800	4,574,431	172,294	Jul 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 01 '26	Sale	272.90	3,000	818,710	134,643	Jul 06 09:05 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Jul 06 '26	Proposed Sale	280.00	1,000	280,000		Jul 06 04:56 PM
DANIEL RABINOWITZ	Officer	Jul 01 '26	Proposed Sale	271.45	16,800	4,560,360		Jul 01 04:15 PM
SOLOMON MOSHKEVICH	Officer	Jul 01 '26	Proposed Sale	272.90	3,000	818,710		Jul 01 04:13 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jun 24 '26	Sale	251.65	33,600	8,455,355	189,094	Jun 26 09:05 PM
ROSENMAN HERM	Director	Jun 24 '26	Sale	250.00	16,530	4,132,500	4,250	Jun 26 09:05 PM
DANIEL RABINOWITZ	Officer	Jun 24 '26	Proposed Sale	234.76	33,600	7,887,936		Jun 24 04:36 PM
HERMAN ROSENMAN	Director	Jun 24 '26	Proposed Sale	250.00	16,530	4,132,500		Jun 24 04:21 PM
Sheena Jonathan	CO-FOUNDER	Jun 17 '26	Sale	219.87	1,500	329,810	18,782	Jun 22 09:05 PM
Chapman Rowan E	Director	Jun 16 '26	Sale	216.78	2,964	642,536	3,124	Jun 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 15 '26	Sale	211.14	3,150	665,087	249,352	Jun 17 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 15 '26	Sale	214.91	50,000	10,745,662	2,277,843	Jun 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 12 '26	Sale	214.03	50,000	10,701,645	2,327,843	Jun 16 09:35 PM
ROWAN EMMA CHAPMAN	Director	Jun 16 '26	Proposed Sale	216.78	2,964	642,536		Jun 16 04:02 PM
MATTHEW RABINOWITZ	Director	Jun 12 '26	Proposed Sale	219.23	100,000	21,923,000		Jun 12 04:42 PM
Marcus Gail Boxer	Director	Jun 05 '26	Option Exercise	22.83	11,000	251,130	17,183	Jun 09 09:05 PM
Marcus Gail Boxer	Director	Jun 05 '26	Sale	217.21	11,000	2,389,328	6,183	Jun 09 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 04 '26	Sale	221.03	41,124	9,089,776	108,743	Jun 05 09:05 PM
GAIL MARCUS	Director	Jun 05 '26	Proposed Sale	217.21	11,000	2,389,328		Jun 05 05:15 PM
STEVEN L CHAPMAN	Officer	Jun 04 '26	Proposed Sale	221.03	41,124	9,089,778		Jun 04 05:03 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jun 01 '26	Sale	218.43	3,000	655,295	137,643	Jun 03 09:05 PM
BOTHA ROELOF	Director	Jun 01 '26	Sale	220.31	78,000	17,184,092	1,076,198	Jun 03 04:40 PM
BV369 TRUST	Affiliate	Jun 01 '26	Proposed Sale	220.31	78,000	17,184,094		Jun 01 04:12 PM
SOLOMON MOSHKEVICH	Officer	Jun 01 '26	Proposed Sale	218.43	3,000	655,295		Jun 01 04:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 26 '26	Sale	202.84	1,652	335,091	140,643	May 28 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 26 '26	Sale	202.84	1,438	291,684	185,782	May 28 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 08 '26	Sale	208.60	3,150	657,104	252,502	May 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 13 '26	Sale	201.56	1,500	302,347	19,532	May 15 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 05 '26	Sale	213.77	6,986	1,493,363	2,376,402	May 06 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 04 '26	Sale	206.16	722	148,848	2,382,440	May 06 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 04 '26	Sale	210.49	482	101,456	57,496	May 05 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	206.16	313	64,528	57,978	May 05 09:45 PM
Sheena Jonathan	CO-FOUNDER	May 01 '26	Sale	206.16	107	22,059	255,652	May 05 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 01 '26	Sale	203.69	3,405	693,560	142,295	May 05 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 01 '26	Sale	206.16	291	59,993	187,220	May 05 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	May 01 '26	Sale	206.16	902	185,956	149,867	May 05 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	May 01 '26	Sale	206.16	330	68,033	222,694	May 05 09:35 PM
MICHAEL BROPHY	Officer	May 04 '26	Proposed Sale	207.28	482	99,909		May 04 04:52 PM
SOLOMON MOSHKEVICH	Officer	May 01 '26	Proposed Sale	203.35	3,000	610,065		May 01 04:08 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 29 '26	Sale	193.74	3,070	594,789	58,291	Apr 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 27 '26	Sale	204.14	1,993	406,856	61,361	Apr 29 09:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your Finviz experience